Clinical Trial Update: Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating paroxetine controlled-release for major depressive disorder in irritable bowel syndrome patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Major Depressive Disorder

Drugs mentioned

• Paroxetine controlled release (paroxetine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder | Phase 4 | Status: WITHDRAWN